Ariela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.
Ariela Noy, MD
Advertisement
Articles by Ariela Noy, MD
Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt LymphomaDecember 18th 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5